龙济男子医院在武清区割包皮到天津武清龙济怎么样,天津武清区龙济早泄治,包皮龙济,津西客运站与武清区龙济医院男科医院近吗,天津龙济医院在呢么样,龙济网址,武清区龙济医院好吗可靠吗

BEIJING, Feb. 19 (Xinhua) -- As the traditional Spring Festival season ended two days ago, a new wave of post-holiday travel rush came to China's railway system, the Ministry of Railways (MOR) said Saturday.According to a statement from the MOR, the nation's railways carried 6.49 million passengers on Friday, the first day after the Lantern Festival which ended the festival season.The new wave of passengers mainly included students going back to school for the new semester and migrant workers returning to cities to start work. On Friday alone, 919,000 student passenger trips were made on railways, said the MOR.The ministry expected the travel volume and duration of the new peak to be similar to the previous year, with an average of more than 6 million railway passenger trips a daily.The MOR figures also showed that 166 million trips were made on railways since the Spring Festival travel rush began on Jan. 19, up 6 percent from the same period last year.

BEIJING, Jan. 25 (Xinhua) -- The central parity rate of yuan, the Chinese currency, Tuesday gained 2 points to 6.5881 against the U.S. dollar, according to the China Foreign Exchange Trading System.China's central bank announced in June 2010 it would further reform the exchange rate formation mechanism to improve its flexibility.On China's foreign exchange spot market, the yuan can rise or fall 0.5 percent from the central parity rate each trading day.The central parity rate of the RMB against the U.S. dollar is based on a weighted average of prices before the opening of the market each business day.

BRUSSELS, April 29 (Xinhua) -- As a 2004 European Union (EU) directive on herbal medicine is to be fully implemented on May 1, herbal medicinal products without a license will no longer be allowed in the EU market, the European Commission said in a press release Friday.The Traditional Herbal Medicinal Products Directive, adopted by the EU member states in 2004, introduced a so-called simplified registration procedure with a seven-year transition period for traditional herbal medicinal products to obtain a medicine license.As the transition period is to expire on Saturday, herbal medicinal products from home and abroad, most of which have been sold as food supplements for decades, need to be medically registered or authorized by EU governments in order to remain in the market after May 1.Instead of going through safety tests and clinical trials as regular chemical drugs, applicants are required by the directive to provide documents showing the herbal medicinal product is not harmful in the specified condition of use, as well as evidence that the product at least has a 30-year history of safe use, including 15 years in the EU.However, a wide range of eligibility and technical challenges along with prohibitive costs have so far prevented both local and outside herbal medicinal products from being granted the license.Only a small proportion of indigenous herbal medicinal products have been approved for registration while not a single Chinese or Indian traditional herbal medicinal products have been licensed.Lack of pan-European rules, EU member states had adopted different approaches to herbal medicine, thus creating a "state of anarchy" in the markets despite the fact that indigenous herbs had a 700-year history of use in Europe.Although the directive was intended to harmonize rules of member states and build a level-playing field across the EU, critics argued that the directive may fall short of the aim and create more chaos and uncertainties for the industry.DRAWBACKSThe directive has been under attack for being neither "adequate " nor "appropriate" due to its high registration cost for a single product and its lack of consideration about the Chinese and Indian traditional herbal medicine.Chris Dhaenens, a licensed herbalist in Belgium and a shareholder of a medium-sized herbal importing company doing business with China and ten European countries, said the directive was only appropriate for companies carrying a few products and who could afford the registration costs."It is simply inaccessible to most players distributing high- quality Chinese or Indian herbal products in Europe," he said, adding that the registration fee for a single product could be as high as 150,000 euros.The Alliance for Natural Health, a British-based group representing herbal practitioners, estimated the cost of obtaining a license at between 80,000 and 120,000 pounds (90,000 to 135,000 U.S. dollars) per herb.Dhaenens, who is also the president of the European Benefyt Foundation, a leading traditional medicine group in Europe, argued that the directive only tried to regulate herbal products instead of its practitioners and the whole herbal system, as well as fell short to take the Chinese and Indian traditional medicine into full consideration.Even the European Commission had admitted that the directive was not fit for the registration of Chinese and Indian medicine in an earlier exchange with the European Medicine Agency in Dec. 2008, Dhaenens revealed in an exclusive interview with Xinhua."But they had no money or time to work out an alternative, and so it was left to the member states," he said.

VIENNA, April 12 (Xinhua) -- A protein group has been identified as an "allergy multiplier" that causes food allergy, a symptom that could also accompany other allergies and produce serious consequences, Austrian researchers said Tuesday.The so-called non-specific lipid transfer proteins (nsLTP) are believed to be the causes of food allergy, a research team from the Medical University of Vienna said in a new report.These plant allergens are found not only in many fruits and vegetables, but also in cereals and some types of pollen. Due to their compact structures, they are not degraded in the gastrointestinal tract and can trigger immune reactions that cause severe allergic symptoms, said the report.The researchers believe that with nsLTP identified as an " allergy multiplier," diagnostic and treatment procedures could be adapted and improved.

COPENHAGEN, April 30 (Xinhua) -- As traditional Chinese medicine (known as TCM in Europe) becomes increasingly popular worldwide and has gradually been regarded as a useful component to Western medical treatments, Denmark is no stranger to such trends.According to a study published by the University of Copenhagen in mid-Feb., up to one-third of Danish hospitals choose complementary or alternative therapies, including TCM methods, to treat pain, cancer, mental disease, tumors and infertility. Acupuncture remains the most widely-practiced form of these treatments, used in some 97 percent of the cases.The nationwide acceptance of acupuncture and massage therapists, the growing ranks of herbal practitioners, and the hosting of an annual pan-Scandinavian TCM conference since 2007, all underline the popularity of alternative medicine, including the TCM, in the country.However, the overall market presence of TCM, and herbal medicines in particular, is relatively small in Denmark and Europe at large. As many European policymakers insist that traditional herbal medicines "are neither scientifically documented nor tested according to Western requirements," these treatments face difficulties in obtaining licenses and boosting sales in Europe.In fact, despite their historical pedigree and widely-accepted efficacy, TCM products are often classified as "healthcare products" or "food," rather than "drugs" in European markets.A big challenge for TCM products to gain more access to the continent is the EU's Traditional Herbal Medicinal Products Directive, which stipulates that all such products must obtain authorization if they are to be sold within the EU, starting May 1, 2011.The directive says producers must prove the product in question has been used for 30 years, 15 of which within the EU, so as to ensure its safety.While licensing is expected to be onerous and expensive, Denmark has tried to bring TCM products into the Western medical mainstream from as early as 2005. The country's well-developed biochemical and medical industry, modernized agriculture and horticulture sectors and a strong track record of cooperative research in these fields, has helped TCM's cause.For instance, Traditional Complementary Medicine Denmark, a company helping herbal product makers market their goods in Western countries, uses modern biotechnology processes and clinical trials to scientifically verify and document the efficacy of existing herbal medicines.It also advises herbal product makers on how to align their standards with European requirements so as to acquire the necessary sales licenses. Sometimes, simple solutions like clearer and more detailed labeling of a TCM product's ingredients can help improve its marketability. Patent applications and drug approvals procedures must follow, before the product can access the EU pharmaceutical market, usually in pill form.Investing in herbal medicine also makes financial sense for Denmark, as it is encourages development of low-bulk, high-value agricultural products, which can be easily transported all over the globe.Development Centre Aarslev, a Danish agro-research body and partner of TCM Denmark, studies the active ingredients contained in medicinal plants and their impact on human health conditions such as cardiovascular problems, diabetes and allergies. One of the earliest collaborations it undertook with a producer of herbal medicine showed the effectiveness of extracts from the hips of the dog rose plant in treating rheumatoid arthritis.A spokesperson for the institution said, "We have documented analytical evidence which shows that arthritis patients can reduce their consumption of conventional anti-arthritis drugs by up to 50 percent, if they combine them with the herbal drug based on dog rose hips."Given Denmark's population of 5.5 million people, this could translate into savings of 200 million U.S. dollars a year on anti-arthritis medication, the spokesperson added.Other plant-based interventions could hold wider public health benefits. TCM practitioners say herbal medicines can improve blood circulation in humans, and contain naturally-occurring antioxidants which can reduce the risks of heart attacks and better regulate cardiovascular functions. This has potentially wide-ranging benefit for Western societies, where heart disease is a major threat.Heart disease was the most common cause of death in Denmark until 2000, and cardiovascular disease the commonest until 2008, with cancer now ranking the biggest killer.In fact, TCM herbal remedies are also considered a good choice for cancer treatment, as certain plants contain hormone-like substance which can influence hormone-dependent cancers, such as breast and prostate cancer.TCM supporters say the obvious benefit of such an intervention is the avoidance of more commonly-used chemotherapy and radiation treatments which often produce severe side-effects in patients. Relevant herbal therapies can help strengthen cancer patient's immune system, reduce side-effects of chemotherapy and radiation therapy, and alleviate other symptoms of the disease.Given the many potential benefits of TCM, the EU's tightening of rules may appear harsh. Still, TCM is considered a relatively novel approach to medicine in Europe. Moreover, the dominant market share and general clout of the chemical-based, Western pharmaceutical industry also makes it difficult for traditional remedies to stake their claim.